Official Positions for FRAX® clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.
Details
Serval ID
serval:BIB_D598908841E1
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Official Positions for FRAX® clinical regarding biochemical markers from Joint Official Positions Development Conference of the International Society for Clinical Densitometry and International Osteoporosis Foundation on FRAX®.
Journal
Journal of Clinical Densitometry
Working group(s)
FRAX(®) Position Development Conference Members
Contributor(s)
Hans DB., Cooper C., Baim S., Dawson-Hughes B., Kanis JA., Leslie WD., Luckey MM., Rizzoli R., Poiana C., Bilezekian JP., Papapoulos SE., McCloskey EV., Binkley N., Adachi JD., Baim S., Blank RD., Boonen S., Broy SB., Bruyere O., Chandran M., Cooper C., Dawson-Hughes B., Eastell R., Ensrud K., Dimai HP., Foldes J., Garnero P., Geusen PP., Griesmacher A., Hannan MT., Kanis JA., Kleerekoper M., Krieg MA., Langdahl B., Laster A., Leib ES., Masud T., McClung M., Morris H., Ortolani S., Saag KG., Siris E., Silverman S., Bobo Tanner S., Trenti T., Vasikaran S., Vestergaard P., Wahl DA., Michael Lewiecki E., Compston JE., Adachi JD., Adams JE., Adler RA., Bauer DC., Blake GM., Clark P., Diez-Perez A., Hans DB., Josse RG., Kanis JA., Kendler DL., Khan AA., Krieg MA., Leslie WD., Lorenc RR., Moayyeri A., Masri BK., Miller PD., Cauley JA., Fuleihan el-HG., Arabi A., Calderon A., Chen Z., Chionh SB., Curtis J., Danielson ME., Fujiwara S., Hanley D., Kroger H., Kung A., Lesnyak O., Looker A., Luckey MM., Mellstrom D., Nieves J., Pluskiewicz W., Rassi RE., Rizzoli R., Ragi-Eis S., Silverman S., Schott-Pethelaz A., Bilezekian JP., Papapoulos SE., Adachi JD., Blank RD., Chapurlat R., Chih-Hsing W., Czerwinski E., Perez AD., Dimai HP., Fuleihan el-HG., Fujiwara S., Ionescu RM., Kanis JA., McClung M., Stepan J., Ragi-Eis S., Saag KG., Schousboe JT., Yu W., Zerbini C., Brown PD., McKenney P., Johansson H., Nagy J., Oden A., Wahl DA.
ISSN
1094-6950 (Print)
ISSN-L
1094-6950
Publication state
Published
Issued date
2011
Volume
14
Number
3
Pages
220-222
Language
english
Notes
Publication types: Consensus Development Conference ; Journal Article
Publication Status: ppublish
Publication Status: ppublish
Abstract
The best indirect evidence that increased bone turnover contributes to fracture risk is the fact that most of the proven therapies for osteoporosis are inhibitors of bone turnover. The evidence base that we can use biochemical markers of bone turnover in the assessment of fracture risk is somewhat less convincing. This relates to natural variability in the markers, problems with the assays, disparity in the statistical analyses of relevant studies and the independence of their contribution to fracture risk. More research is clearly required to address these deficiencies before biochemical markers might contribute a useful independent risk factor for inclusion in FRAX(®).
Keywords
Absorptiometry, Photon, Biological Markers/blood, Bone Density, Bone Remodeling, Diagnosis, Computer-Assisted, Femur Neck/radiography, Fractures, Bone/diagnosis, Fractures, Bone/etiology, Humans, Osteoporosis/diagnosis, Osteoporotic Fractures/diagnosis, Risk Assessment, Risk Factors
Pubmed
Web of science
Create date
28/02/2012 12:59
Last modification date
20/08/2019 16:55
Usage data
